Avalon GloboCare (NASDAQ:ALBT) Trading Down 1.4% – Should You Sell?

Avalon GloboCare Corp. (NASDAQ:ALBT)’s stock price dropped 1.4% during mid-day trading on Monday . The company traded as low as $2.15 and last traded at $2.19. Approximately 26,365 shares were traded during trading, a decline of 40% from the average daily volume of 44,263 shares. The stock had previously closed at $2.22.

Analyst Upgrades and Downgrades

ALBT has been the subject of a number of research reports. Wall Street Zen lowered shares of Avalon GloboCare to a “strong sell” rating in a research note on Saturday, September 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Avalon GloboCare in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Avalon GloboCare currently has an average rating of “Sell”.

Avalon GloboCare Price Performance

The firm has a market cap of $8.41 million, a P/E ratio of -0.42 and a beta of 0.03. The stock’s 50 day moving average is $2.33 and its two-hundred day moving average is $2.82.

Avalon GloboCare (NASDAQ:ALBT) last posted its earnings results on Thursday, August 14th. The company reported ($2.02) earnings per share for the quarter. The company had revenue of $0.35 million for the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.